| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000018888 |
| Receipt No. | R000021838 |
| Scientific Title | Foods with Function Claims: Empirical studies for "Mibyo (presymptomatic state) prevention", "Health Promotion", "Become healthy", "Can walk lightly" and "Rejuvenate" by intake of eggshell membrane dietary supplement, TO-II BEAUTY EVOLUTION |
| Date of disclosure of the study information | 2015/09/02 |
| Last modified on | 2021/03/06 (Ver. 6) |
| Basic information | ||
| Public title | Foods with Function Claims: Empirical studies for "Mibyo (presymptomatic state) prevention", "Health Promotion", "Become healthy", "Can walk lightly" and "Rejuvenate" by intake of eggshell membrane dietary supplement, TO-II BEAUTY EVOLUTION | |
| Acronym | Empirical studies on the effects of eggshell membrane dietary supplement | |
| Scientific Title | Foods with Function Claims: Empirical studies for "Mibyo (presymptomatic state) prevention", "Health Promotion", "Become healthy", "Can walk lightly" and "Rejuvenate" by intake of eggshell membrane dietary supplement, TO-II BEAUTY EVOLUTION | |
| Scientific Title:Acronym | Empirical studies on the effects of eggshell membrane dietary supplement | |
| Region |
|
|
| Condition | ||
| Condition | Aging | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Evaluating the "Mibyo (presymptomatic state) prevention", "Health Promotion", "Become healthy", "Can walk lightly" and "Rejuvenation" effects of taking oral eggshell membrane supplements |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Improvement of lung function, skin elasticity, and diversity of intestinal microflora after two months of taking eggshell membrane supplements. |
| Key secondary outcomes | Maximal oxygen uptake, standing posture, height, weight, BMI, dietary survey, heart rate, respiratory rate, walking speed, resting pulse, ventilatory work threshold, grip strength, blood cytokine hormone, blood test, urine test, sit-ups, psychological test, arterial stiffness, body composition, zigzag walk, back muscle strength, leg muscle strength, dustpan, repetitive lateral jump, long sit Body bending, long sit forward bending, liver stiffness, back skin elasticity, video recording, two-step test, information on lifestyle, arm skin moisture, oil, and transpiration, skin stratum corneum lipid profile measurement, and bone density measurement (all assessed before, 3 weeks, 4 weeks, 8 weeks, and 12 weeks after intake) |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Cluster |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is not considered as adjustment factor. |
| Blocking | NO |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral intake of eggshell membrane contained supplements (During 3 months, 4 tablets in every morning and evening) | |
| Interventions/Control_2 | Oral intake of eggshell membrane removed supplements (During 3 months, 4 tablets in every morning and evening) | |
| Interventions/Control_3 | Oral intake of placebo tablets with all components of the supplements removed (During 3 months, 4 tablets in every morning and evening) | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Healthy males and females older than 20 years and younger than 65 years, 30 in total number | |||
| Key exclusion criteria | Persons suffering from diseases, persons who are taking-ingested drugs and foods to bring any influence on the experiment, persons who can not tolerate the experiment physically, smokers | |||
| Target sample size | 30 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Tokyo University of Agriculture and Technology | ||||||
| Division name | Graduate School of Engineering, Department of Applied Chemistry | ||||||
| Zip code | |||||||
| Address | 2-24-16 Nakacho, Koganei, Tokyo | ||||||
| TEL | 042-388-7289 | ||||||
| toshi@cc.tuat.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tokyo University of Agriculture and Technology | ||||||
| Division name | Grad Sch of Eng, Dept of Appl Chem | ||||||
| Zip code | |||||||
| Address | 2-24-16 Nakacho, Koganei, Tokyo | ||||||
| TEL | 042-388-7539 | ||||||
| Homepage URL | |||||||
| mshmz@cc.tuat.ac.jp | |||||||
| Sponsor | |
| Institute | Tokyo University of Agriculture and Technology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Almado Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 東京農工大学(東京都) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB | |||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000021838 |